Petros Pharma officer granted 375K PTPI shares

Boctor Fady reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Boctor Fady reported acquisition or exercise transactions in this Form 4 filing.

Petros Pharmaceuticals, Inc. reported that officer Fady Boctor received a grant of 375,000 shares of common stock as equity compensation. The filing states that 50% of these restricted shares vested on the grant date, while the remaining 50% will vest after six months if he continues providing services, bringing his direct holdings to 894,986 shares.

Insider Trade Summary

Grant/Award: 375,000 shares

Grant/Award 1 txn

Insider Boctor Fady

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	375,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 894,986 shares (Direct)

Footnotes (1)

1. F1. Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.

Key Figures

Restricted stock grant: 375,000 shares Grant price per share: $0.00 per share Post-transaction holdings: 894,986 shares +2 more

5 metrics

Restricted stock grant 375,000 shares Common Stock grant to Fady Boctor

Grant price per share $0.00 per share Equity compensation, not open-market purchase

Post-transaction holdings 894,986 shares Direct ownership after grant

Immediate vesting portion 50% Vests on grant date

Delayed vesting portion 50% Vests six months after grant if services continue

Key Terms

restricted shares, vesting, par value, grant, award, or other acquisition

4 terms

restricted shares financial

"Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer."

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

vesting financial

"50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

par value financial

"restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer."

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Petros Pharmaceuticals (PTPI) report in this Form 4 for Fady Boctor?

Petros Pharmaceuticals reported that officer Fady Boctor received 375,000 restricted common shares as a grant. The transaction is recorded at a price of $0.00 per share and increases his direct holdings to 894,986 common shares of the company.

How many PTPI shares did Fady Boctor acquire in this insider transaction?

Fady Boctor acquired 375,000 restricted shares of Petros Pharmaceuticals common stock. These shares were granted as equity compensation, with no cash price per share, and are subject to a time-based vesting schedule described in the Form 4 footnote.

What is the vesting schedule for Fady Boctor’s 375,000 PTPI restricted shares?

The Form 4 states that 50% of the restricted shares vested on the grant date. The remaining 50% will vest on the six-month anniversary of the grant, provided Fady Boctor is still providing services to Petros Pharmaceuticals on that vesting date.

What are Fady Boctor’s total PTPI holdings after this Form 4 transaction?

After the grant of restricted stock, Fady Boctor directly holds 894,986 shares of Petros Pharmaceuticals common stock. This total reflects his position immediately following the acquisition transaction disclosed in the Form 4 filing.

Was Fady Boctor’s PTPI share grant an open-market purchase or compensation award?

The transaction is classified as a grant or award acquisition, not an open-market purchase. The Form 4 shows a transaction code “A” with a $0.00 price per share, indicating equity compensation rather than a market buy order.

Does Fady Boctor’s PTPI restricted stock grant have performance conditions?

The description in the Form 4 indicates a time-based condition only. It states that the remaining 50% of the restricted shares vest at six months if Fady Boctor continues providing services, with no additional performance targets mentioned in the excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 05:25 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boctor Fady

(Last) (First) (Middle)

1185 AVENUE OF THE AMERICAS, 3RD FLOOR

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Petros Pharmaceuticals, Inc. [ PTPI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		A		375,000(1)	A	$0(1)	894,986	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.

Remarks:

President & Chief Commercial Officer

	/s/ Fady Boctor	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)